Summary
Thermo Fisher Scientific Inc. reported first quarter 2023 revenues of $10.71 billion, a decrease of 9% year-over-year, primarily driven by a significant decline in COVID-19 related revenue. Despite the top-line decrease, the company demonstrated resilience with adjusted operating income of $2.33 billion and adjusted EPS of $5.03, reflecting strong pricing and productivity measures. The company also continues to execute its growth strategy, including strategic investments and a notable acquisition of The Binding Site Group in January 2023 for $2.7 billion, which is expected to bolster its Specialty Diagnostics segment. Cash flow from operations was $729 million, though free cash flow saw a substantial decrease to $277 million compared to $1.56 billion in the prior year period, largely due to higher investments in working capital and acquisitions. The company maintained a strong balance sheet with approximately $3.5 billion in cash and equivalents and continued its commitment to shareholders through share repurchases totaling $3.0 billion in the quarter, while maintaining its credit facility capacity. Management remains confident in the company's ability to meet its financial obligations and fund its ongoing operations and strategic initiatives.
Financial Highlights
54 data points| Revenue | $10.71B |
| R&D Expenses | $346.00M |
| SG&A Expenses | $2.12B |
| Operating Expenses | $9.15B |
| Operating Income | $1.56B |
| Interest Expense | $300.00M |
| Net Income | $1.29B |
| EPS (Basic) | $3.34 |
| EPS (Diluted) | $3.32 |
| Shares Outstanding (Basic) | 386.00M |
| Shares Outstanding (Diluted) | 388.00M |
Key Highlights
- 1Total revenues for Q1 2023 were $10.71 billion, a 9% decrease year-over-year, largely attributed to a significant drop in COVID-19 related sales ($141M in Q1 2023 vs $1.68B in Q1 2022).
- 2Adjusted operating income decreased by 32% to $2.33 billion, and adjusted diluted EPS fell 31% to $5.03, reflecting lower COVID-19 volumes and unfavorable business mix, partially offset by pricing and productivity initiatives.
- 3The Life Sciences Solutions segment experienced a significant 38% revenue decline, primarily due to the moderation of COVID-19 related revenue, while the Analytical Instruments segment showed strong growth (14%).
- 4Thermo Fisher completed the acquisition of The Binding Site Group for $2.7 billion in January 2023, aimed at enhancing its Specialty Diagnostics segment.
- 5Free cash flow significantly decreased to $277 million in Q1 2023 from $1.56 billion in Q1 2022, impacted by investments in working capital and acquisitions.
- 6The company repurchased $3.0 billion of its common stock in Q1 2023, demonstrating a continued commitment to returning capital to shareholders.
- 7Despite a decrease in current assets, particularly cash and cash equivalents ($3.48B from $8.52B), the company maintains a robust financial position with $35.3B in total debt and ample liquidity via its credit facilities.